Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SVR005
MIFTS: 50

Severe Pre-Eclampsia

Categories: Cardiovascular diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Severe Pre-Eclampsia

About this section

MalaCards integrated aliases for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 12 54 15 71 32
Severe Preeclampsia 12 15
Severe Pre-Eclampsia, Antepartum Condition or Complication 71
Severe Pre-Eclampsia, Postpartum Condition or Complication 71
Severe Pre-Eclampsia, with Delivery 12
Antepartum Severe Pre-Eclampsia 12
Postpartum Severe Pre-Eclampsia 12
Severe Toxemia 71

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:13129
ICD9CM 34 642.50
ICD10 32 O14.1
UMLS 71 C0156669 C0156672 C0156673 more
Sources

Summaries for Severe Pre-Eclampsia

About this section
Disease Ontology : 12 A pre-eclampsia that has symptom at least one of the following: SBP of 160mm HG or higher or DPB of 110mm HG or higher on 2 occasions at least 6 hours apart, proteinuria more than 5g in a 24-hour collection, pulmonary edema or cyanosis, oliguria, persistent headaches, epigastric pain and/or impaired liver function, thrombocytopenia, oligohydramnios, decreased fetal growth or placental abruption.

MalaCards based summary : Severe Pre-Eclampsia, also known as severe preeclampsia, is related to acute kidney failure and thrombotic microangiopathy, and has symptoms including at least one of the following An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Pathways in cancer. The drugs Azithromycin and Tinzaparin have been mentioned in the context of this disorder. Affiliated tissues include placenta, liver and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Sources

Related Diseases for Severe Pre-Eclampsia

About this section

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 367)
# Related Disease Score Top Affiliating Genes
1 acute kidney failure 31.2 GPT CFH ALB
2 thrombotic microangiopathy 31.0 VEGFA CFH
3 hellp syndrome 30.9 VEGFA SERPINC1 PGF LGALS13 LEP GPT
4 eclampsia 30.9 VEGFA SERPINC1 PGF PAPPA LGALS13 HLA-G
5 antiphospholipid syndrome 30.7 VCAM1 SERPINC1 PGF F5 CFH C3
6 mild pre-eclampsia 30.7 VEGFA VCAM1 PGF PAPPA LGALS13 LEP
7 oligohydramnios 30.6 PGF PAPPA FGR
8 membranoproliferative glomerulonephritis 30.5 CFH C3 ALB
9 pericardial effusion 30.5 VEGFA HIF1A GPT ALB
10 end stage renal disease 30.5 VEGFA CFH C3 ALB
11 hyperuricemia 30.5 LEP GPT ALB
12 brain edema 30.3 VEGFA MMP9 ALB
13 kidney disease 30.3 VCAM1 LEP FN1 CFH C3 ALB
14 cholelithiasis 30.3 LEP GPT ALB
15 hyperglycemia 30.3 VCAM1 LEP HIF1A ALB
16 gestational diabetes 30.2 PGF PAPPA LEP ALB
17 glomerulonephritis 30.2 VCAM1 FN1 CFH C3 ALB
18 purpura 30.2 SERPINC1 C3 APOH
19 ovarian hyperstimulation syndrome 30.2 VEGFA F5 ALB
20 disseminated intravascular coagulation 30.1 SERPINC1 GPT FN1 F5
21 hemolytic-uremic syndrome 30.1 SERPINC1 CFH C3
22 polyarteritis nodosa 30.0 VCAM1 GPT APOH
23 thrombotic thrombocytopenic purpura 30.0 SERPINC1 CFH C3 APOH
24 autoimmune disease 29.9 VCAM1 MMP9 HLA-G C3 APOH
25 amaurosis fugax 29.9 MMP9 F5
26 liver cirrhosis 29.9 SERPINC1 LEP GPT ALB
27 migraine with or without aura 1 29.8 MMP9 LEP APOH ALB
28 thrombophilia due to thrombin defect 29.8 SERPINC1 F5 APOH
29 placenta praevia 29.7 PGF PAPPA
30 papilledema 29.7 VEGFA SERPINC1 APOH
31 cardiovascular system disease 29.6 VCAM1 SERPINC1 LEP APLN ALB
32 chronic kidney disease 29.6 VEGFA VCAM1 MMP9 LEP FN1 CFH
33 placental abruption 29.6 SERPINC1 PGF PAPPA HLA-G F5 APOH
34 placental insufficiency 29.5 VEGFA SERPINC1 PGF PAPPA LEP HIF1A
35 hepatic infarction 29.5 SERPINC1 GPT APOH ALB
36 endocarditis 29.5 VCAM1 SERPINC1 APOH ALB
37 cerebrovascular disease 29.5 VCAM1 MMP9 LEP F5 APOH
38 pulmonary embolism 29.4 SERPINC1 F5 APOH ALB
39 thrombophilia due to activated protein c resistance 29.3 SERPINC1 F5 APOH
40 antithrombin iii deficiency 29.3 SERPINC1 F5 APOH
41 intracranial hypertension 29.2 SERPINC1 F5 APOH ALB
42 thrombosis 29.2 VCAM1 SERPINC1 F5 APOH
43 homocysteinemia 29.2 VCAM1 SERPINC1 F5 APOH ALB
44 pre-eclampsia 29.1 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9
45 protein s deficiency 29.1 SERPINC1 F5 APOH
46 budd-chiari syndrome 29.0 SERPINC1 F5 APOH
47 blood coagulation disease 29.0 VEGFA SERPINC1 GPT F5 APOH ALB
48 thrombocytopenia 28.8 SERPINC1 MMP9 HIF1A GPT F5 CFH
49 hypertension, essential 28.6 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9
50 placenta disease 28.6 VEGFA SERPINC1 PGF PAPPA HLA-G F5

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia
Sources

Symptoms & Phenotypes for Severe Pre-Eclampsia

About this section

Symptoms:

12
  • • at least one of the following

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.39 ALB APLN C3 CFH F5 FGR
2 homeostasis/metabolism MP:0005376 10.34 ALB APLN APOH C3 CFH F5
3 growth/size/body region MP:0005378 10.26 APLN C3 CFH F5 FN1 HIF1A
4 immune system MP:0005387 10.22 ALB C3 CFH FGR FN1 HIF1A
5 hematopoietic system MP:0005397 10.2 C3 CFH FGR FN1 HIF1A HLA-G
6 embryo MP:0005380 10.19 APLN C3 F5 FN1 HIF1A LEP
7 liver/biliary system MP:0005370 9.97 ALB C3 F5 FN1 HIF1A LEP
8 muscle MP:0005369 9.97 ALB APLN C3 CFH FN1 HIF1A
9 normal MP:0002873 9.81 ALB C3 CFH FGR FN1 HIF1A
10 neoplasm MP:0002006 9.8 ALB FN1 HIF1A LEP MMP9 PGF
11 renal/urinary system MP:0005367 9.56 ALB C3 CFH HIF1A LEP MMP9
12 vision/eye MP:0005391 9.28 APLN C3 CFH HIF1A LEP MMP9
Sources

Drugs & Therapeutics for Severe Pre-Eclampsia

About this section

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4 83905-01-5 447043 55185
2
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
3
Dalteparin Approved Phase 4 9005-49-6
4
Enoxaparin Approved Phase 4 9005-49-6 772
5
Ephedrine Approved Phase 4 299-42-3 9294
6
Pseudoephedrine Approved Phase 4 90-82-4 7028
7
leucovorin Approved Phase 4 58-05-9 6006 143
8
Clonidine Approved Phase 4 4205-90-7 2803
9
Captopril Approved Phase 4 62571-86-2 44093
10
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
11
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14 Anti-Infective Agents Phase 4
15 Anti-Bacterial Agents Phase 4
16 Adrenergic alpha-Agonists Phase 4
17 Sympatholytics Phase 4
18 Adrenergic Agonists Phase 4
19 Antibodies Phase 4
20 Immunoglobulins Phase 4
21 Antibodies, Antiphospholipid Phase 4
22 Heparin, Low-Molecular-Weight Phase 4
23 Central Nervous System Stimulants Phase 4
24 Vasoconstrictor Agents Phase 4
25 Vitamin B Complex Phase 4
26 Hematinics Phase 4
27 Folate Phase 4
28 Vitamin B9 Phase 4
29 Angiotensin-Converting Enzyme Inhibitors Phase 4
30 Iron Supplement Phase 4
31 Lactoferrin Phase 4
32 Sodium Potassium Chloride Symporter Inhibitors Phase 4
33 diuretics Phase 4
34 Sodium Channel Blockers Phase 4
35 Anesthetics, Local Phase 4
36 Diuretics, Potassium Sparing Phase 4
37 Analgesics Phase 4
38 Anesthetics Phase 4
39 Anti-Arrhythmia Agents Phase 4
40 Anticonvulsants Phase 4
41
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
42
Misoprostol Approved Phase 3 59122-46-2 5282381
43
Carbetocin Approved, Investigational Phase 3 37025-55-1 71715 16681432
44
Digoxin Approved Phase 2, Phase 3 20830-75-5 30322 2724385
45
Nicardipine Approved, Investigational Phase 3 55985-32-5 4474
46
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
47
Titanium dioxide Approved Phase 3 13463-67-7
48
Povidone Approved Phase 3 9003-39-8
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
50 Urapidil Investigational Phase 3 34661-75-1

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Continuation Versus Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Unknown status NCT03318211 Phase 4 Magnesium Sulfate
3 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Among Egyptian Primigravidae: a Randomized Controlled Trial Unknown status NCT03233880 Phase 4 Azithromycin 1gm
4 Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial. Completed NCT03164304 Phase 4 Magnesium Sulfate
5 Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
6 A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
7 Low Molecular Weight Heparin for Treatment of Recurrent Miscarriage With Negative Antiphospholipid Antibodies: a Randomized Controlled Trial Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
8 Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
9 Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
10 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
11 Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women Completed NCT01221844 Phase 4 FerroGrad by Abbott
12 Prophylactic Ephedrine to Reduce Fetal Bradycardia After Combined Spinal Epidural Labor Analgesia: a Randomized Double Blind Placebo-controlled Study Completed NCT02062801 Phase 4 Ephedrine;Placebo
13 Postpartum Management of Gestational Hypertensive Disorders Using Furosemide: A Randomized Controlled Trial Enrolling by invitation NCT04343235 Phase 4 furosemide;labetalol
14 Lignocaine Nebulization for Attenuation of Intubation Stress Response in Patients With Severe Pre-eclampsia: a Prospective Double-blinded Placebo-controlled Trial Not yet recruiting NCT04441073 Phase 4 Lignocaine;Placebo
15 Effectiveness and Safety of 1g/Hour vs. 2g/Hour of Magnesium Sulfate Maintenance Dose for Eclampsia Prevention: Randomized Clinical Trial Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
16 Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
17 Oral Nifedipine Versus IV Labetalol in Treatment of Severe Pre Eclampsia in Pregnancy Unknown status NCT03325348 Phase 2, Phase 3 Nifedipine 10 mg;Labetalol
18 Carbetocin Versus Oxytocin for Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia: a Double Blind Randomized Controlled Trial Unknown status NCT01382732 Phase 3 Carbetocin;Oxytocin
19 Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial Unknown status NCT03237819 Phase 3 Sulfate, Magnesium;Placebo - Concentrate
20 Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial Unknown status NCT03262961 Phase 2, Phase 3 Sildenafil 20 MG;Placebo Oral Tablet
21 Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia. Completed NCT02086994 Phase 3 misoprostol;carbetocin
22 Ibuprofen Versus Acetaminophen in Women With Severe Pre-eclampsia After Vaginal Delivery. Completed NCT01988298 Phase 2, Phase 3 Ibuprofen;Acetaminophen
23 The Best Magnesium Sulphate Protocol for Severe Pre-eclampsia : A Randomized Controlled Trial Completed NCT01846156 Phase 3 MgSO4
24 A Novel Protocol for Postpartum Magnesium Sulfate in Severe Preeclampsia When the Woman Received Less That 8 Hours Before Delivery. Six Versus Twenty-four Hours Postpartum Completed NCT02317146 Phase 2, Phase 3 Magnesium Sulfate
25 Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial . Completed NCT02307201 Phase 2, Phase 3 Magnesium Sulfate
26 Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial Completed NCT00986765 Phase 3 Lovenox® (enoxaparin);Aspegic ® (Aspirin)
27 Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy and Death in Preterm Infants (MASP-STUDY) Completed NCT01492608 Phase 3 Magnesium sulphate
28 A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia Recruiting NCT03008616 Phase 2, Phase 3
29 A Phase 3, Randomized, Placebo-controlled, Double Blind Study of KW-3357 in Patients With Early Onset Severe Preeclampsia Recruiting NCT04182373 Phase 3 Antithrombin gamma;physiological saline
30 The Treatment of Hypertension Associated With Severe Preeclampsia. A Randomize Controlled Trial of Urapidil Versus Nicardipine. The Uranic Trial Active, not recruiting NCT02558023 Phase 3 Urapidil;Nicardipine
31 Investigating the Role of Early Low-dose Aspirin in Diabetes: A Phase III Multicentre Double-blinded Placebo-controlled Randomised Trial of Low-dose Aspirin Initiated in the First Trimester of Diabetes Pregnancy Not yet recruiting NCT03574909 Phase 3 Aspirin;Placebos
32 Maternal and Neonatal Outcomes After the Use of Vasopressors to Correct Hypotension During Cesarean Section Under Spinal Anesthesia in Pregnant Women With Severe Preeclampsia: Randomized Clinical Trial Withdrawn NCT01451060 Phase 3 Metaraminol;Ephedrine
33 Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery Withdrawn NCT01796522 Phase 3 progesterone 200 mg / day vaginally;nifedipine (60 mg / day orally)
34 Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET) Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
35 Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
36 A Parallel, Double-blind, Placebo Controlled, Randomized Comparison of an Anti-digoxin Antibody (Digibind) Versus Placebo for the Treatment of Antepartum Patients With Severe Preeclampsia Completed NCT00158743 Phase 2 Anti-digoxin antibody (FAB fragment)
37 Comparison Between Dexmedetomidine and Remifentanil on the Maternal Responses to Tracheal Intubation in Severe Pre-eclamptic Patients During Caesarean Delivery Completed NCT01766089 Phase 2 Remifentanil;Dexmedetomidine
38 Sleep Disordered Breathing and Preeclampsia Completed NCT00259688 Phase 2
39 Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients at a Tertiary Care Hospital of Karachi. Completed NCT02050529 Phase 2 Labetalol;Hydralazine
40 Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia Recruiting NCT03667326 Phase 2 Aspirin;Placebo oral capsule
41 Preeclampsia And Nonsteroidal Drugs for Analgesia (PANDA): a Randomized Non Inferiority Trial Recruiting NCT03978767 Phase 2 Ibuprofen 600 mg;Ketorolac;Acetaminophen;Oxycodone
42 Pravastatin to Prevent Preeclampsia and Reduce Maternal-Neonatal Mortality and Morbidity in High Risk Preeclampsia Patients Recruiting NCT03648970 Phase 2 Pravastatin
43 Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy) Recruiting NCT03152058 Phase 2 Certolizumab Pegol
44 Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation Terminated NCT02286284 Phase 2
45 Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia: a Randomized, Placebo-controlled Trial Completed NCT03451266 Phase 1 Vitamin C;placebo
46 A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia Suspended NCT00333307 Phase 1 recombinant human relaxin
47 Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study. Unknown status NCT01538121
48 Spinal Anesthesia in Severe Preeclampsia and Its Impact on Hemodynamics (Case Control Study) Unknown status NCT02633995
49 Sublingual Microcirculation Change in Pregnant Women With or Without High Risk Pregnancy Factors During Pregnancy and Postpartum Period Unknown status NCT03476096
50 CA-125 and Severity of Pre-Eclampsia Unknown status NCT02704676

Search NIH Clinical Center for Severe Pre-Eclampsia

Sources

Genetic Tests for Severe Pre-Eclampsia

About this section
Sources

Anatomical Context for Severe Pre-Eclampsia

About this section

MalaCards organs/tissues related to Severe Pre-Eclampsia:

40
Placenta, Liver, Endothelial, Testes, Kidney, Heart, Lung
Sources

Publications for Severe Pre-Eclampsia

About this section

Articles related to Severe Pre-Eclampsia:

(show top 50) (show all 3704)
# Title Authors PMID Year
1
The 3'-untranslated region of the HLA-G gene in relation to pre-eclampsia: revisited. 61 54
20070604 2010
2
Soluble human leukocyte antigen-G isoforms in maternal plasma in early and late pregnancy. 61 54
19811467 2009
3
Is there any link between severe pre-eclampsia and defined polymorphisms in leptin and adiponectin genes? 61 54
18958929 2008
4
Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial. 54 61
18226126 2008
5
Effect of sera on the adhesion of natural killer cells to the endothelium in severe pre-eclampsia. 61 54
16984509 2006
6
[Expression of Fas antigen and ligand, placental growth factor in placenta of pregnant women with pre-eclampsia]. 54 61
15938782 2005
7
Maternal and fetal single nucleotide polymorphisms in the epoxide hydrolase and gluthatione S-transferase P1 genes are not associated with pre-eclampsia in the Coloured population of the Western Cape, South Africa. 54 61
16147638 2004
8
Recent progress in the therapeutic management of pre-eclampsia. 61 54
15500369 2004
9
Serum leptin levels and uterine Doppler flow velocimetry at 20 weeks' gestation as markers for the development of pre-eclampsia. 61 54
15697078 2004
10
Serum levels of leptin, insulin-like growth factor-I and insulin-like growth factor binding protein-3 in women with pre-eclampsia, and their relationship to insulin resistance. 61 54
15497497 2004
11
Serum levels of insulin, IGF-1, and IGFBP-1 in pre-eclampsia and eclampsia. 61 54
15001368 2004
12
Antinuclear antibody testing in obstetric patients. 54 61
14750494 2003
13
Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. 61 54
12572596 2002
14
Is there an increased maternal-infant prevalence of Factor V Leiden in association with severe pre-eclampsia? 61 54
11888101 2002
15
The expression and activity of monoamine oxidase A, but not of the serotonin transporter, is decreased in human placenta from pre-eclamptic pregnancies. 61 54
11133008 2000
16
Transport and metabolism of serotonin in the human placenta from normal and severely pre-eclamptic pregnancies. 61 54
10729753 2000
17
Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia. 54 61
10611266 2000
18
Studies on the HLA-DRB1 genotypes in Japanese women with severe pre-eclampsia positive and negative for anticardiolipin antibody using a polymerase chain reaction-restriction fragment length polymorphism method. 61 54
10601082 1999
19
Vascular cell adhesion molecule-1 (VCAM-1) and leukocyte activation in pre-eclampsia and eclampsia. 61 54
9856316 1998
20
Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. 54 61
9712539 1998
21
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. 54 61
8863672 1996
22
Insulin-like growth factors and their binding proteins in normal and abnormal human fetal growth. 54 61
7532055 1994
23
Lupus anticoagulant in pre-eclampsia and intra-uterine growth retardation. 61 54
1773868 1991
24
Dynamic changes in cardiac function before and early postdelivery in women with severe preeclampsia. 61
32195819 2020
25
Prevention of preeclampsia in high-risk patients with low-molecular-weight heparin: a meta-analysis. 61
30458652 2020
26
Serum endocan concentration and its correlation with severity of hypertensive disorders in pregnancy. 61
30501553 2020
27
Identifying cardiovascular severe maternal morbidity in epidemiologic studies. 61
31971615 2020
28
Severe maternal morbidity surveillance: Monitoring pregnant women at high risk for prolonged hospitalisation and death. 61
31407359 2020
29
Prepregnancy body mass indexes are associated with perinatal outcomes in females with preeclampsia. 61
32509020 2020
30
Serum magnesium levels in normal pregnant women, severe preeclampsia, and severe preeclampsia with complications; a consideration for early supplementation? 61
32545134 2020
31
Placental Production of Eicosanoids and Sphingolipids in Women Who Developed Preeclampsia on Low-Dose Aspirin. 61
32557282 2020
32
Expression and clinical diagnostic value of miR-383 in patients with severe preeclampsia. 61
32538753 2020
33
Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. 61
32443079 2020
34
Landscape of Dysregulated Placental RNA Editing Associated With Preeclampsia. 61
32306769 2020
35
Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. 61
32443077 2020
36
Why can't I exercise during pregnancy? Time to revisit medical 'absolute' and 'relative' contraindications: systematic review of evidence of harm and a call to action. 61
32513676 2020
37
Preeclampsia and the anaesthesiologist: current management. 61
32049882 2020
38
Severe pre-eclamptic women with headache: is posterior reversible encephalopathy syndrome an associated concurrent finding? 61
32487027 2020
39
Assessing multidimensional care coverage for pre-eclampsia in the era of universal health coverage: A pre-post evaluation of the Salud Mesoamérica Initiative. 61
32112708 2020
40
Up-regulated cytotrophoblast DOCK4 contributes to over-invasion in placenta accreta spectrum. 61
32576693 2020
41
[HELLP Syndrome: clinical-analytical characteristics and evolution observed in two years of experience]. 61
32532671 2020
42
Maternal Hypertensive Pregnancy Disorders and Mental Disorders in Children. 61
32306771 2020
43
Association of fetal gender and the onset and severity of hypertensive disorders of pregnancy. 61
32576066 2020
44
Restless Legs Syndrome and Severe Preeclampsia: A Case-Control Study. 61
32576450 2020
45
Surviving mothers and lost babies - burden of stillbirths and neonatal deaths among women with maternal near miss in eastern Ethiopia: a prospective cohort study. 61
32373341 2020
46
SARS-CoV-2 infection of the placenta. 61
32573498 2020
47
Antiphospholipid syndrome presenting as treatment resistant bipolar disorder and thrombocytopenia in a young male. 61
32305000 2020
48
The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis. 61
32338457 2020
49
Expression imbalance of IL-17/IL-35 in peripheral blood and placental tissue of pregnant women in preeclampsia. 61
32416889 2020
50
Shortened postpartum magnesium sulfate treatment vs traditional 24h for severe preeclampsia: a systematic review and meta-analysis of randomized trials. 61
32338165 2020
Sources

Variations for Severe Pre-Eclampsia

About this section
Sources

Expression for Severe Pre-Eclampsia

About this section
Search GEO for disease gene expression data for Severe Pre-Eclampsia.
Sources

Pathways for Severe Pre-Eclampsia

About this section

Pathways related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.1 VEGFA SERPINC1 FN1 FGR F5 APOH
2
Pathways in cancer 36
12.63 VEGFA PGF MMP9 HIF1A FN1
3
Proteoglycans in cancer 36
12.05 VEGFA MMP9 HIF1A FN1
4
Complement and coagulation cascades 36 1
11.78 SERPINC1 F5 CFH C3
5
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.69 VCAM1 LEP FN1
6
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.66 VEGFA PGF HIF1A
7
HIF-1-alpha transcription factor network 1
11.45 VEGFA LEP HIF1A
8
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.38 VEGFA VCAM1 MMP9
9
amb2 Integrin signaling 1
11.23 MMP9 FN1 FGR
10
Interleukin-4 and 13 signaling 65
11.08 VEGFA VCAM1 MMP9 HIF1A FN1
11
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 10.91 VEGFA LEP HIF1A
12
Glypican 1 network 1
10.75 VEGFA SERPINC1 FGR
13
Angiogenesis (WikiPathways) 1
10.51 VEGFA MMP9 HIF1A
14
miR-148a/miR-31/FIH1/HIF1andalpha;-Notch signaling in glioblastoma 1
10.45 VEGFA HIF1A
Sources

GO Terms for Severe Pre-Eclampsia

About this section

Cellular components related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.02 VCAM1 SERPINC1 MMP9 GPT FN1 FGR
2 extracellular region GO:0005576 9.86 VEGFA SERPINC1 PGF PAPPA MMP9 LEP
3 endoplasmic reticulum lumen GO:0005788 9.77 SERPINC1 FN1 F5 C3 ALB
4 platelet alpha granule lumen GO:0031093 9.56 VEGFA FN1 F5 ALB
5 blood microparticle GO:0072562 9.55 SERPINC1 FN1 CFH C3 ALB
6 extracellular space GO:0005615 9.53 VEGFA VCAM1 SERPINC1 PGF PAPPA MMP9

Biological processes related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 VEGFA PGF LEP FN1 APLN
2 negative regulation of apoptotic process GO:0043066 9.97 VEGFA MMP9 LEP HIF1A ALB
3 cytokine-mediated signaling pathway GO:0019221 9.83 VEGFA VCAM1 MMP9 HIF1A FN1
4 response to hypoxia GO:0001666 9.8 VEGFA PGF LEP HIF1A
5 post-translational protein modification GO:0043687 9.8 SERPINC1 HIF1A FN1 F5 C3 ALB
6 positive regulation of angiogenesis GO:0045766 9.78 VEGFA PGF HIF1A C3
7 positive regulation of protein phosphorylation GO:0001934 9.77 VEGFA PGF MMP9 LEP C3
8 female pregnancy GO:0007565 9.76 PGF PAPPA LEP
9 positive regulation of endothelial cell proliferation GO:0001938 9.71 VEGFA PGF HIF1A
10 induction of positive chemotaxis GO:0050930 9.59 VEGFA PGF
11 regulation of blood coagulation GO:0030193 9.56 SERPINC1 APOH
12 lactation GO:0007595 9.56 VEGFA SERPINC1 HIF1A APLN
13 complement activation, alternative pathway GO:0006957 9.55 CFH C3
14 platelet degranulation GO:0002576 9.55 VEGFA FN1 F5 APOH ALB
15 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.52 VEGFA HIF1A
16 positive regulation of mast cell chemotaxis GO:0060754 9.51 VEGFA PGF
17 negative regulation of vasoconstriction GO:0045906 9.46 LEP APLN
18 angiogenesis GO:0001525 9.43 VEGFA PGF LEP HIF1A FN1 APLN
19 elastin metabolic process GO:0051541 9.4 LEP HIF1A
20 cellular protein metabolic process GO:0044267 9.1 SERPINC1 PAPPA FN1 F5 C3 ALB

Molecular functions related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.65 VEGFA SERPINC1 PGF MMP9 HLA-G FN1
2 signaling receptor binding GO:0005102 9.63 LEP HLA-G FN1 FGR C3 APLN
3 vascular endothelial growth factor receptor binding GO:0005172 9.26 VEGFA PGF
4 heparin binding GO:0008201 9.1 VEGFA SERPINC1 PGF FN1 CFH APOH
Sources

Sources for Severe Pre-Eclampsia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....